CSL112
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Objective— CSL112 (apolipoprotein A-I [apoA-I; human]) is a novel formulation of apoA-I in development for reduction of early…
CSL112 (apolipoprotein A‐I [human]) is a novel intravenous formulation of plasma‐derived apolipoprotein A‐I (apoA‐I) that…
CSL112 (Apolipoprotein A‐I [human]) is an intravenous preparation of apolipoprotein A‐I (apoA‐I), formulated with…
ABSTRACT Introduction: The risk of major adverse cardiac events (MACE) remains elevated soon after a coronary event. High-density…
Background: Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein–mediated…
Clinical intervention studies have provided clear evidence that low‐density lipoproteins are causally involved in the development…
Objective— The ability of apolipoprotein A-I (apoA-I) to transport cholesterol from atherosclerotic plaque is thought to underlie…
CSL112 is apoA‐I purified from human plasma and reconstituted with phosphatidylcholine (PC) to form high‐density lipoprotein (HDL…
Objective—The ability of high-density lipoprotein (HDL) to remove cholesterol from atherosclerotic plaque is thought to underlie…